Recently,XbiomeWith China's leading probiotics enterprisesWonderLab(hereinafter referred to as: WonderLab) Research cooperation results "Screen of Propionate-producing Probiotic Strains in Attenuating Murine Colitis by Modulating Immune Response and Restoring the Intestinal Barrier", published in an academic journal Journal of Functional Foods Officially published.
This achievement introduces two strains of probiotics:Xbiome's self-developed patented Bifidobacterium breve XA-2103, as well as Lactobacillus plantarum GOLDGUT-PA0755 co-developed by Xbiome and WonderLab, both have a positive impact on symptoms of inflammatory bowel disease.
It is reported that Inflammatory Bowel Disease (hereinafter referred to as IBD) is a chronic intestinal disease closely associated with an increased risk of gastrointestinal cancer. Currently, the main treatments for IBD are immunosuppressants and other medications or surgeries targeting clinical manifestations, but these two therapies may bring side effects and complications to patients. At present, there is an urgent demand among patients for milder treatments such as nutritional supplements or probiotics, making the effective screening of probiotics for IBD treatment a focal point of scientific research.
Studies have found that the reduction in gut microbiota diversity is one of the main factors in the pathogenesis of IBD. Alterations in gut microbiota lead to metabolic disturbances, which directly or indirectly increase pro-inflammatory immune cells, thereby influencing the progression of the disease. Therefore, evaluating the ability of probiotics to produce key metabolites is a feasible strategy for screening effective probiotics. There have been numerous reports demonstrating that short-chain fatty acids, especially butyrate, help enhance the integrity and function of intestinal epithelial cells, playing a positive role in alleviating intestinal inflammation. Propionate, similar to butyrate, also plays a crucial role in regulating gut homeostasis; however, compared with the majority of studies on butyrate, research on propionate-producing probiotics is relatively limited. This article further explores this "blue ocean" research field, aiming to screen and discover novel probiotic strains, which may bring new opportunities for patients with IBD.
Based on this status quo, the scientific team of Xbiome, combined with the company's own vast strain library and the comprehensive dry and wet lab systems and AI algorithms from its R&D platform, has developed a set of"Funnel"-shaped strain screening platform,Through a series of processes including whole-genome analysis, metabolite prediction, metabolite identification, and in vivo and in vitro functional validation, two "IBD killers" were successfully and efficiently screened from tens of thousands of strains containing thousands of probiotics:Bifidobacterium breve XA-2103 and Pediococcus acidilactici GOLDGUT-PA0755.
In this study conducted in Journal of Functional Foods In the published study, Xbiome and the WonderLab scientific team conducted extensive research and validation on the functions and mechanisms of Bifidobacterium breve XA-2103 and Lactobacillus plantarum GOLDGUT-PA0755. The results showed that,Both probiotic strains demonstrated considerable anti-inflammatory capabilities.Reduced the level of inflammatory factors in peripheral blood mononuclear cells. In addition,They also play a protective role in maintaining intestinal integrity.Up-regulate the expression of tight junction proteins in models with impaired intestinal epithelial integrity. In subsequent animal model validation experiments,They also showed a direct alleviating effect on colitis symptoms.Such as improving weight loss, IBD disease activity index, as well as ameliorating colon length and colonic histopathological structure, etc. The above research results indicate that XA-2103 and GOLDGUT-PA0755 have positive and beneficial therapeutic effects on IBD.
Notably, the short Bifidobacterium XA-2103 selected this time is one of Xbiome's self-developed "star" strains.Previously, Xbiome had conducted in-depth research on the impact of this strain on intestinal diseases and applied for a national invention patent.According to the patent specification, XA-2103 not only significantly reduces the secretion of cellular inflammatory factors and maintains the integrity of the intestinal barrier in in vitro evaluations, but also significantly alleviates disease indicators of ulcerative colitis induced by DSS (dextran sulfate sodium salt, an anionic derivative that can induce a colitis model) in in vivo animal experiments, markedly decreasing the overall inflammation levels in experimental animals.
XA-2103 has once again been "shortlisted" in this screening for IBD, and the research findings have been published, serving as a dual validation of the strain's functionality and Xbiome's strain screening platform technology capabilities.
Currently, Xbiome and WonderLab's scientific teams are deepening their collaboration in the field of strain function exploration, with continuous achievements in research and commercialization. Relying on a vast strain library and an AI microbiome research and product development platform that integrates "dry lab" and "wet lab" approaches, Xbiome can achieve full-process R&D from foundational scientific research, strain screening, and functional validation to commercial transformation, providing scientifically evidenced high-quality products and R&D solutions for partners in the probiotics industry.
-End-